News commentary: Human embryonic stem cell therapy in the post-Geron era

Regenerative Medicine

Volumn 7, Issue 1, 2012, Pages 17-18

  Brindley, David ^a,b,c   Mason, Chris ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c HARVARD BUSINESS SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; COST BENEFIT ANALYSIS; EMBRYONIC STEM CELL; HEALTH CARE COST; HUMAN; INVESTMENT; MARKETING; MEDICAL TECHNOLOGY; NOTE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; RESEARCH PRIORITY; RESOURCE ALLOCATION; SPINAL CORD INJURY; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; BIOTECHNOLOGY; CYTOLOGY; ECONOMICS;

BIOTECHNOLOGY; EMBRYONIC STEM CELLS; HUMANS; STEM CELL TRANSPLANTATION;

EID: 83655184087     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.11.115     Document Type: Note

References (2)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 282(5391), 1145-1147 (2011).
2. Brindley DA, Reeve BC, Sahlman WA et al. The impact of market volatility on the cell therapy industry. Cell Stem Cell 9(5), 397-401 (2011).